Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Coleus forskohlii root extract is standardised for forskolin, which activates adenylate cyclase and increases cAMP. Used for fat loss and testosterone support. Lowers blood pressure (avoid with antihypertensives), inhibits platelet aggregation (avoid with anticoagulants). May affect thyroid hormones. Contraindicated in peptic ulcer disease and pregnancy.
Biological and Chemical Classification
- Scientific Name
- Coleus forskohlii
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Coleus Forskohlii indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 9/10 |
| Evidence transparency | 9/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:12
Evidence Distribution
-
Observational / other LOW evidence YELLOWBiogenic synthesis of gold nanoparticles using Coleus forskohlii leaf extract enhances anticancer activity against HT-29 cells and modulates the p53 regulated immune… ↗Suliman M et al.. Biogenic synthesis of gold nanoparticles using Coleus forskohlii leaf extract enhances anticancer activity against HT-29 cells and modulates the p53 regulated immune microenvironment in colon adenocarcinoma.. Sci Rep. 2026. PMID:41554852.PMID 41554852 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41554852/
-
Observational / other LOW evidence YELLOWHeterologous Production of Forskolin in Tobacco (Nicotiana tabacum) via Glandular Trichome Specific Engineering and Metabolic Flux Redirection. ↗Sun X et al.. Heterologous Production of Forskolin in Tobacco (Nicotiana tabacum) via Glandular Trichome Specific Engineering and Metabolic Flux Redirection.. Plant Biotechnol J. 2026. PMID:41147720.PMID 41147720 ↗Journal Plant Biotechnol JYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41147720/
-
Observational / other LOW evidence YELLOWA Novel Nanocombination of Lactoferrin With Green Synthesized Zinc Oxide Nanoparticles for Alleviating Bleomycin-Induced Oxidative Stress and Cardiotoxicity in Male Rats. ↗Ashry M et al.. A Novel Nanocombination of Lactoferrin With Green Synthesized Zinc Oxide Nanoparticles for Alleviating Bleomycin-Induced Oxidative Stress and Cardiotoxicity in Male Rats.. J Biochem Mol Toxicol. 2025. PMID:41276482.PMID 41276482 ↗Journal J Biochem Mol ToxicolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41276482/
-
Observational / other LOW evidence YELLOWIsoforskolin, adenylate cyclase agonist, inhibits endothelial-to-mesenchymal transition in atherosclerosis. ↗Ma Y et al.. Isoforskolin, adenylate cyclase agonist, inhibits endothelial-to-mesenchymal transition in atherosclerosis.. Phytomedicine. 2025. PMID:39986229.PMID 39986229 ↗Journal PhytomedicineYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39986229/
-
Observational / other LOW evidence YELLOWFlow Injection Analysis-Mass Spectrometry for the fast detection of frauds in Coleus forskohlii food supplements. ↗Jimu00e9nez-Amezcua I et al.. Flow Injection Analysis-Mass Spectrometry for the fast detection of frauds in Coleus forskohlii food supplements.. J Chromatogr A. 2025. PMID:39616828.PMID 39616828 ↗Journal J Chromatogr AYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39616828/
-
Observational / other LOW evidence YELLOWHigh-frequency shoot regeneration, assessment of genetic fidelity, and histochemical analysis of forskolin production in Coleus forskohlii Briq. ↗Mitra M et al.. High-frequency shoot regeneration, assessment of genetic fidelity, and histochemical analysis of forskolin production in Coleus forskohlii Briq.. Protoplasma. 2025. PMID:39549044.PMID 39549044 ↗Journal ProtoplasmaYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39549044/
-
Observational / other LOW evidence YELLOWHealth Benefits of Epigallocatechin Gallate and Forskolin with a Special Emphasis on Glaucoma and Other Retinal Diseases. ↗Rusciano D. Health Benefits of Epigallocatechin Gallate and Forskolin with a Special Emphasis on Glaucoma and Other Retinal Diseases.. Medicina (Kaunas). 2024. PMID:39768839.PMID 39768839 ↗Journal Medicina (Kaunas)Year 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39768839/
-
Observational / other LOW evidence YELLOWNot all cytochrome b5s are created equal: How a specific CytB5 boosts forskolin biosynthesis in Saccharomyces cerevisiae. ↗Forman V et al.. Not all cytochrome b5s are created equal: How a specific CytB5 boosts forskolin biosynthesis in Saccharomyces cerevisiae.. Metab Eng. 2024. PMID:39454871.PMID 39454871 ↗Journal Metab EngYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39454871/
-
Observational / other LOW evidence YELLOWEnhancement of Forskolin Production Using Aeroponic Cultivation of Coleus forskohlii and the Impact on the Plant Phytochemistry. ↗Le Cabec A et al.. Enhancement of Forskolin Production Using Aeroponic Cultivation of Coleus forskohlii and the Impact on the Plant Phytochemistry.. Molecules. 2024. PMID:39275064.PMID 39275064 ↗Journal MoleculesYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39275064/
-
Observational / other LOW evidence YELLOWColeus. ↗Coleus.. 2006. PMID:30000934.PMID 30000934 ↗Year 2006Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/30000934/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Coleus Forskohlii. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Coleus Forskohlii
A score of 4.0 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.